Centromere protein F (CENP-F), a cell cycle-regulated centromere protein, has been shown to affect numerous tumorigenic processes. This study aimed to clarify the prognostic significance of CENP-F expression in patients with esophageal squamous cell carcinoma (ESCC). The levels of CENP-F messenger RNA and protein were higher in ESCC cell lines than in the normal tissues. An immunohistochemical analysis of paired tissue specimens showed that the CENP-F expression was higher in tumorous tissues than in the adjacent non-tumorous tissues (P<0.001). Moreover, there was a significant correlation between CENP-F expression and gender (P=0.012), clinical stage (P=0.039), and T classification (P=0.026). Patients with higher CENP-F expression had shorter overall survival than those with lower CENP-F expression (P=0.009). Multivariate Cox analysis indicated that CENP-F expression is an independent prognostic factor for overall survival (hazard ratio=0.582, 95% confidence interval=0.397-0.804, P=0.041). Importantly, it was found that zoledronic acid (ZOL) could significantly enhance the chemotherapeutic sensitivity of ESCC cell lines with high CENP-F expression to cisplatin, although ZOL alone only exhibited a minor inhibitory effect to ESCC cells. In summary, these findings demonstrate that CENP-F may serve as a valuable molecular marker for predicting the prognosis of ESCC patients. In addition, the data indicate a potential benefit of combining ZOL with cisplatin in ESCC, suggesting that CENP-F expression may have therapeutic implications. © 2012 the Authors © 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
CITATION STYLE
Mi, Y. J., Gao, J., Xie, J. D., Cao, J. Y., Cui, S. X., Gao, H. J., … Chen, Y. Q. (2013). Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Diseases of the Esophagus, 26(6), 636–643. https://doi.org/10.1111/dote.12002
Mendeley helps you to discover research relevant for your work.